01 — At a Glance
The Pharma Darling That Just Got Acquired (Sort Of)
- 52-Week High / Low₹2,115 / ₹1,303
- Q3 FY26 Revenue (TTM)₹4,193 Cr
- Q3 FY26 PAT₹198 Cr
- Q3 EPS (₹)₹12.63
- Annualised EPS (Q3×4)₹50.52
- Book Value₹243
- Price to Book8.54x
- Dividend Yield0.78%
- Debt / Equity0.01x
- Torrent Acquisition (Jan 2026)₹1,639.18 / share (open offer)
Auditor’s Opening Note: J.B. Chemicals closed Q3 FY26 with a quarterly revenue of ₹1,065 crore (+11% YoY), ₹198 crore PAT (+22% YoY), and a 44.2x P/E that screams “acquisition premium.” The company is the fastest-growing in the top 25 Indian pharma companies by IPM and just became controlled by Torrent Pharma through a January 2026 acquisition triggered at ₹1,639.18 per share. The merger swap is 51:100 — meaning for every 100 shares of JB Pharma, you get 51 Torrent shares. The deal isn’t done yet. The stock has barely budged. Let’s figure out why.
02 — Introduction
The Pharma Play That Became a Merger Casualty
J.B. Chemicals and Pharmaceuticals is what happens when a 1976-founded pharma company decides to play the long game: build sustainable brands, own 35%+ market share in 5+ molecule categories, scale to ₹4,193 crore annual revenue, and then get bought by someone bigger for multiples you didn’t bargain for.
The company has zero debt (literally ₹7.3 crore as of Sep 2025, down from ₹14 crore as of Mar 2025). It prints money. It grows 11–12% annually, outpacing the industry by 200–300 basis points. Its domestic formulations business — the heart of the operation — just logged a ₹620 crore quarter with +10% YoY growth while outperforming IPM. The international business is firing on all cylinders: 20% growth in export formulations, CDMO stabilizing at a ₹115–120 crore quarterly run-rate, and pilots in Russia and South Africa building momentum.
Then on June 29, 2025, Torrent Pharmaceuticals announced it would acquire 46.39% of JB Chemicals for ₹11,917 crore from Tau Investment Holdings (a KKR affiliate). Open offer for another 26% followed. Board control shifted. Three directors exited. A CEO appointed. CFO tumbled. The machinery of a PE-style transaction started churning, and the stock — which should have rallied on the deal certainty — instead remained glued to ₹1,800–₹2,100 for months. Welcome to pharma M&A in a merger-weary market.
Concall Note (Jan 2026): “Merger can happen any time, 6 to 9 months from closure” — Management’s diplomatic way of saying “we have no idea when this is closing and neither do you.” The deal is technically not locked. It is “work in progress” at “normal speed.” Read: limbo.
03 — Business Model: WTF Are Pharmaceuticals Even?
Pills, Potions, and the Art of Chronic Domination
J.B. Chemicals manufactures and markets pharmaceutical formulations across three verticals: domestic (58% of revenue), export (42%), and niche contract manufacturing. The company holds dominant positions in gastroenterology (Metrogyl, Rantac), cardiovascular (Nicardia, Cilacar), antibiotics, and pain management. Its brands have penetrated into the top 150 (and some into top 100) by revenue across IQVIA’s tracking.
Domestically, the business operates a three-pronged model: field force physicians (cardiac, gastro, antibiotic franchises), brand distribution through pharmacists and retail channels, and franchise partnerships (Sporlac, for probiotics). The international business splits further: regulated market generics (USA, Canada, Australia), emerging market branded generics (Africa, Latin America, CIS), and contract manufacturing of lozenges for global marquee clients — where JB ranks in the top 5 globally.
What’s remarkable: the company actually has pricing power in India. Q3 saw domestic price hikes of approximately 7%, and management guided ₹620 crore domestic revenue with 10% YoY growth. Competitive intensity is real — but JB’s brand equity and distribution network have kept pricing stickiness intact. This is not a margin story powered by volume sacrifice; it’s a margin story powered by pricing + chronic mix shift + operational efficiency.
Domestic58%Revenue Mix
International42%Revenue Mix
Chronic Skew↑ 45%Of Domestic Mix
Field Force2,600+Medical Reps
Franchise Note: Cilacar (cardiac) +25%, Cilacar-T (cardiac combo) +33%, Nicardia (vasodilator) +30%. These brands are not coasting — they’re actively taking market share from generics and smaller regional players. Management explicitly positioned chronic portfolio as the “higher side” of growth, a signal that mix expansion is not just commentary but actual execution.
💬 Question for you: In a world of generic ARVs and 5G biotech memes, does a company that sells heart pills and stomach remedies bore you? Or do profits matter more than narrative?
04 — Financials Overview
Q3 FY26: The Numbers That Matter (And the Merger Discount That Doesn’t)
Result type: Quarterly Results | Q3 FY26 EPS: ₹12.63 | Annualised EPS (Q3×4): ₹50.52 | TTM (Trailing Twelve Months) EPS: ₹48.23
| Metric (₹ Cr) |
Q3 FY26
Dec 2025 |
Q3 FY25
Dec 2024 |
Q2 FY26
Sep 2025 |
YoY % |
QoQ % |
| Revenue | 1,065 | 963 | 1,085 | +10.6% | -1.8% |
| Operating Profit | 296 | 255 | 310 | +16.1% | -4.5% |
| OPM % | 28% | 26% | 29% | +200 bps | -100 bps |
| PAT | 198 | 162 | 208 | +22.2% | -4.8% |
| EPS (₹) | 12.63 | 10.45 | 13.27 | +20.9% | -4.8% |
P/E Recalculated: TTM EPS ₹48.23 ÷ CMP ₹2,074 = P/E 43.0x (screener shows 44.2x, likely rounding or live share count changes). This is a 45–60% premium to sector median P/E of 27.6x. The Torrent deal priced control at ₹1,639.18 per share. At ₹2,074, the minority shareholders are sitting on a 26.5% premium to that price. This is the “deal arbitrage” — the market is betting the merger either doesn’t close, or someone else walks in, or Torrent steps up the offer. For now, uncertainty is being priced as upside.
05 — Valuation: Fair Value Range
What’s This Acquired-But-Not-Really Company Actually Worth?
Join 10,000+ investors who read this every week.
